drugset / Trial / NCT00366106
Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma
Phase 2
Terminated
32 enrolled
Accelerated Community Oncology Research Network
Millennium Pharmaceuticals, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The current study is being conducted to evaluate the possibility that a different schedule of bortezomib, doxorubicin HCl liposome, and dexamethasone might decrease the incidence of peripheral neuropathy yet maintain similar efficacy and allow maintenance of bortezomib dosing for a longer period.
Timeline
- Start
- 2006-07
- Primary completion
- 2011-03
- Completion
- 2011-03
Outcome
Outcome not reported
Stopped (Enrollment): “Study was closed to enrollment when it became clear that enrollment was too slow to complete full enrollment target within time frame allowed.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | — |
| Subject | Dexamethasone | Small molecule | 20 mg | — |
| Subject | Doxorubicin | Other / unclassified | 30 mg/m2 | Intravenous |